Treatment of iron deficiency in patients after acute  decompensation: a new target in the treatment  of heart failure

Жиров, И. В.; Сафронова, Н. В.; Tereshchenko, S. N.

doi:10.15829/1560-4071-2022-4949

Cited by 4 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inorganic smallmolecule iron compounds, as a solution, can release iron quickly but are toxic; however, large-molecule encapsulated iron compounds can induce antibody formation, resulting in allergic reactions [2]. Ferric carboxymaltose has emerged as an ideal intravenous iron preparation thus far [3][4][5][6]. Current research on ferric carboxymaltose is primarily focused on its clinical application [7][8][9], with little investigation into its preparation process.…”

Section: Introductionmentioning

confidence: 99%

Study of H2O2/Cu2+ Catalyzed Oxidation Process of Maltodextrin

et al. 2023

View full text Add to dashboard Cite

In this study, oxidized maltodextrins with a high concentration of carboxyl groups were produced using CuSO4 as a catalyst and H2O2 as an eco-friendly oxidant. Infrared spectroscopy, proton-nuclear magnetic resonance spectroscopy, and thermogravimetric analysis were utilized to examine the structure and properties of oxidized maltodextrins. The reaction conditions were optimized in terms of oxidant content, catalyst content, temperature, pH, and reaction time. The prepared oxidized maltodextrin had a carboxyl group content of 105% under the conditions of 200% molar H2O2, 1% molar catalyst, 55 °C, initial pH = 9.7, and 2 h reaction time. In comparison to the commonly used sodium hypochlorite oxidation process, the carboxyl group content was increased by 58%.

show abstract

Section: Introductionmentioning

confidence: 99%

Study of H2O2/Cu2+ Catalyzed Oxidation Process of Maltodextrin

et al. 2023

View full text Add to dashboard Cite

show abstract

Prevalence and clinical significance of iron deficiency in patients with acute decompensated heart failure

Smirnova,

Sedykh,

Yakushin

et al. 2023

Russ J Cardiol

View full text Add to dashboard Cite

Aim. To study the prevalence of iron deficiency (ID) and anemia, as well as their impact on the clinical performance and quality of life in patients with acute decompensated heart failure (ADHF).Material and methods. The work was performed as part of cross-sectional multicenter screening study of ID in patients with heart failure (HF), managed by the Russian Society of Heart Failure. We examined 80 patients hospitalized in the cardiology department due to ADHF, who signed an informed consent. The diagnosis of ADHF was based on clinical signs of decompensated heart failure requiring intravenous therapy with diuretics, vasodilators, or inotropic agents.Results. The prevalence of ID was 80,0%, anemia — 35,0%, combination of anemia and ID — 31,2%. The mean age of patients with ID was 69,4±10,9 years. Patients with ID had higher HF class (40,6% vs 6,3% without ID, p<0,001), a higher incidence of hydrothorax (65,6% vs 31,3%, p=0,012), higher N-terminal pro-brain natriuretic peptide (5155,5 [3267,3;9786,3] pg/mL vs 2055,5 [708,8;2839,0] pg/mL, p<0,001), lower 6-minute walk test distance (155,9±84,0 m vs 239,6±82,7 m in patients without ID, p=0,01), lower quality of life according to the visual analogue scale (36,4±16,3 vs 46,3±20,7, p=0,036). ID was more often recorded in patients with frailty (95,7% vs 73,7% in patients without frailty, p=0,003), requiring a higher starting dose of intravenous diuretics (50,9±18,9 mg vs 38,6±12,3 mg without ID, p=0,021).Conclusion. In patients hospitalized due to ADHF, the prevalence of ID is 80,0%, anemia — 35,0%, combination of ID and anemia — 31,2%. Patients with ID have a higher N-terminal pro-brain natriuretic peptide level, more severe signs of decompensation, which requires higher starting dose of loop diuretics. Patients with ID are more likely to have frailty, lower exercise tolerance and quality of life.

show abstract

Factors associated with iron deficiency in heart failure

Смирнова

Чижов

2023

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Aim. To establish the factors associated with iron deficiency (ID) in pa- tients with heart failure (HF).Material and methods. We examined 294 patients with NYHA class II-IV HF as follows: 213 — with ID, 81 — without ID. All patients underwent a clinical examination, collection of medical history taking into account the presence, duration and severity of comorbidities, drug history, echocardiography, complete blood count, serum iron, ferritin, transferrin, transferrin saturation, soluble transferrin receptors, hepcidin, erythropoietin, and routine laboratory tests. In addition, we determined the presence and severity of asthenia, anxiety, and depression.Results. Twenty-nine clinical, laboratory and echocardiographic parameters were established, which had significant differences in patients with and without ID and significant correlations with ID. Determining the odds ratio for these 29 parameters revealed 7 factors significantly associated with ID in patients with HF. Using multivariate logistic regression, a significant cumulative effect of these factors on the ID risk was established.Conclusion. ID in patients with HF is associated with age, class II-IV HF, elevated hepcidin levels, duration of hypertension and diabetes, history of using angiotensin-converting enzyme inhibitors and novel oral anticoagulants for >1 year.

show abstract

Treatment of iron deficiency in patients after acute decompensation: a new target in the treatment of heart failure

Cited by 4 publications

References 46 publications

Study of H2O2/Cu2+ Catalyzed Oxidation Process of Maltodextrin

Study of H2O2/Cu2+ Catalyzed Oxidation Process of Maltodextrin

Prevalence and clinical significance of iron deficiency in patients with acute decompensated heart failure

Factors associated with iron deficiency in heart failure

Contact Info

Product

Resources

About